GlassScriptPhysician profile
Elizabeth M Cabrera
NPI 1578960100
$9,851.35
in general payments reported to CMS, 2019-2025
29 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,056 · 2022: $1,759 · 2023: $2,538 · 2024: $1,812 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,856 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,855.65 |
| Education | $180.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,365.65 | 2021-2025 | |
| Janssen Biotech, INC. | $835.31 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $671.24 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $665.72 | 2021-2025 | |
| Amgen INC. | $604.34 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $577.75 | 2021-2025 | Aklief, Oracea, Epsolay |
| Lilly USA, LLC | $573.57 | 2021-2025 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $555.95 | 2021-2025 | |
| Dermavant Sciences, INC. | $530.66 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $523.28 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $484.61 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $448.92 | 2021-2025 | |
| Ucb, INC. | $358.65 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $332.11 | 2021-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $315.20 | 2021-2025 | Ilumya, Odomzo, Blu-U |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $302.32 | 2022-2025 | Opzelura |
| Revance Therapeutics, INC. | $123.95 | 2024-2025 | Daxxify |
| Vyne Pharmaceuticals INC. | $121.70 | 2021 | |
| Kerecis Limited | $95.90 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.20 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $82.55 | 2021 | |
| Organon LLC | $52.31 | 2025 | |
| Mayne Pharma Commercial LLC | $49.69 | 2022-2025 | |
| Allergan, INC. | $18.75 | 2022 | |
| Sandoz INC. | $18.22 | 2023 | Hyrimoz |
| Genentech USA, INC. | $17.96 | 2023 | Xolair |
| Almirall LLC | $16.34 | 2021 | |
| Kyowa Kirin, INC. | $14.63 | 2021 | |
| Biofrontera INC. | $5.87 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.